Ablin R J, Morrell R M
Eur Surg Res. 1976;8(2):140-7. doi: 10.1159/000127855.
Continued utilization of antilymphocyte and antithymocyte sera for clinical use as an immunosuppressant emphasizes the need for a reproducible in vitro assay that will correlate closely with graft protection in vivo. In this regard the in vitro serologic reactivity of antibodies in three preparations of horse anti-human thymocyte globulin (HAHTG) to cell surface antigens of human thymocytes (thymic lymphocytes) as determined by agglutination, cytotoxicity and in particular for the present study by immunofluorescence (IF) have been compared with their in vivo immunosuppressive potency as measured by prolongation of graft survival. Titration by IF of antibodies in HAHTG reactive with surface antigens of cells of the thymolymphatic system appeared to provide a reasonably simple, reliable and complement-independent in vitro correlate of immunosuppressive potency.
抗淋巴细胞血清和抗胸腺细胞血清持续用于临床作为免疫抑制剂，这凸显了需要一种可重复的体外检测方法，该方法要与体内移植物保护密切相关。在这方面，通过凝集、细胞毒性，特别是在本研究中通过免疫荧光（IF）测定的三种马抗人胸腺细胞球蛋白（HAHTG）制剂中的抗体对人胸腺细胞（胸腺淋巴细胞）细胞表面抗原的体外血清学反应性，已与通过移植物存活时间延长所测量的体内免疫抑制效力进行了比较。通过IF对HAHTG中与胸腺淋巴系统细胞表面抗原反应的抗体进行滴定，似乎提供了一种相当简单、可靠且与补体无关的体外免疫抑制效力相关性。
